New developments in diagnosis and treatment update: Schizophrenia/first episode psychosis in children and adolescents

References

• Allen NC, Bagade S, McQueen MB, Ioannidis JP, Kavvoura FK, Khoury MJ, Tanzi RE, Bertram L. 2008. Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nature Genetics40: 827–834.
   PubMed Web of Science ®Google Scholar
• APA (American Psychiatric Association). 2013. Diagnostic and statistical manual of mental disorders (5th edn). Arlington, Virginia: American Psychiatric Publishing.
   Google Scholar
• Almandil NB, Wong ICK. 2011. Review on the current use of antipsychotic drugs in children and adolescents. Archives of Disease in Childhood Education and Practice Edition96: 192–196.
   PubMed Web of Science ®Google Scholar
• Amminger GP, Schafer MR, Papageorgiou K, Klier CM, Cotton SM, Harrigan SM, Mackinnon A, McGorry PD, Berger GE. 2010. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Archives of General Psychiatry67: 146–154.
   PubMed Web of Science ®Google Scholar
• Birchwood M, Todd P, Jackson C. 1998. Early intervention in psychosis. British Journal of Psychiatry172: 53–59.
   PubMed Web of Science ®Google Scholar
• Bradford D, Perkins DO, Lieberman JA. 2003. Pharmacological management of first-episode schizophrenia and related non-affective psychoses. Drugs63: 2265–2283.
   PubMed Web of Science ®Google Scholar
• Cantor-Graae E. 2007. The contribution of social factors to the development of schizophrenia: a review of recent findings. Canadian Journal of Psychiatry52: 277–286.
   PubMed Web of Science ®Google Scholar
• Catts VS, Fung SJ, Long LE, Joshi D, Vercammen A, Allen KA, Fillman SG, Rothmond DA, Sinclair D, Tiwari Y, Tsai SY, Weickert TW, Weickert CS. 2013. Rethinking schizophrenia in the context of normal neurodevelopment. Frontiers in Cellular Neuroscience15: 7–60.
   Google Scholar
• Compton MT, Kelley ME, Ramsay CE. 2009 Association of pre-onset cannabis, alcohol, and tobacco use with age at onset of prodrome and age at onset of psychosis in first-episode patients. American Journal of Psychiatry166: 1251–1257.
   PubMed Web of Science ®Google Scholar
• Correll CU. 2008 Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes. Journal of American Academy of Child and Adolescent Psychiatry47: 9–20.
   PubMed Web of Science ®Google Scholar
• Correll CU, Carlson HE. 2006. Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry45: 7.
   Web of Science ®Google Scholar
• De Hert M, Dobbelaere M, Sheridan EM, Cohen D, Correll CU. 2011 Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice. European Psychiatry26: 144–158.
   PubMed Web of Science ®Google Scholar
• Dhossche D, Ferdinand R, Van Der Ende J. 2002. Diagnostic outcome of self reported hallucinations in a community sample of adolescents. Psychological Medicine32: 619–627.
   PubMed Web of Science ®Google Scholar
• Di Forti M, Sallis H, Allegri F, Trotta A, Ferraro L, Stilo SA, Marconi A, La Cascia C, Marques TR, Pariante C, Dazzan P, Mondelli V, Paparelli A, Kolliakou A, Prata D, Gaugrhan F, David AS, Morgan C, Sthal D, Khondoker M, MacCabe JH, Murray RM. 2013. Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. Schizophrenia Bulletin.
   Google Scholar
• Dragt S, Nieman DH, Veltman D, Becker HE, van de Fliert R, de Haan L, Linszen DH. 2011. Environmental factors and social adjustment as predictors of a first psychosis in subjects at ultra high risk. Schizophrenia Research125: 69–76.
   PubMed Web of Science ®Google Scholar
• Emsley R, Chiliza B, Asmal L, Mashile M, Fusar-Poli P. 2013. Long-acting injectable antipsychotics in early psychosis: a literature review. Early Intervention in Psychiatry7: 247–254.
   PubMed Web of Science ®Google Scholar
• Frangou S. 2013. Neurocognition in early onset schizophrenia. Child and Adolescent Psychiatric Clinics of North America22: 715–726.
   PubMed Web of Science ®Google Scholar
• Freedman J, Wirshing W, Rüssel A. 1994. Absence status seizures after successful long-term clozapine treatment of an adolescent with schizophrenia. Journal of Child and Adolescent Psychopharmacology4: 53–62.
   Web of Science ®Google Scholar
• Gogtay N. 2007. Cortical brain development in schizophrenia: Insights from neuro-imaging studies on childhood onset schizophrenia. Schizophrenia Bulletin34: 30–36.
   PubMed Web of Science ®Google Scholar
• Gerbino-Rosen G, Roofeh D, Tompkins DA. 2005. Haematologic adverse events in clozapine-treated children and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry44: 1024–1031.
   PubMed Web of Science ®Google Scholar
• Griffith-Lendering MFH, Wigman JTW, Prince van Leeuwen A, Huijbregts SCJ, Huizink AC, Ormel J, Verhulst FC, van Os J, Swaab H, Vollebergh WAM. 2013. Cannabis use and vulnerability for psychosis in early adolescence—a TRAILS study. Addiction108: 733–740.
   PubMed Web of Science ®Google Scholar
• Howes OD, Kapur S. 2009. The Dopamine Hypothesis of Schizophrenia: Version III—The final common pathway. Schizophrenia Bulletin35: 549–562, doi:10.1093/schbul/sbp006.
   PubMed Web of Science ®Google Scholar
• Janssen J, Reig S, Parellada M. 2008. Regional gray matter volume deficits in adolescents with first-episode psychosis. Journal of American Academy of Child and Adolescent Psychiatry47: 1311–1320.
   PubMed Web of Science ®Google Scholar
• Kelly D, Conley RR, Carpenter WT. 2005. First-episode schizophrenia: A focus on pharmacological treatment and safety considerations. Drugs65: 1113–1138.
   PubMed Web of Science ®Google Scholar
• Kahn SS, Mican LM. 2006. A naturalistic evaluation of intramuscular ziprasidone versus intramuscular olanzapine for the management of acute agitation and aggression in children and adolescents. Journal of Child Adolescent Psychopharmacology16: 671–677.
   PubMed Web of Science ®Google Scholar
• Kim B, Lee SH, Choi TK. 2008. Effectiveness of risperidone long-acting injection in first-episode schizophrenia: in naturalistic setting. Progress in Neuro-Psychopharmacology and Biological Psychiatry32: 1231–1235.
   PubMed Web of Science ®Google Scholar
• Kumar A, Datta SS, Wright SD, Furtado VA, Russell PS. 2013. Atypical antipsychotics for psychosis in adolescents. Cochrane Review.
   Web of Science ®Google Scholar
• Kumra S, Herion D, Jacobsen LK. 1997. Case study: risperidone-induced hepatotoxicity in paediatric patients. Journal of the American Academy of Child and Adolescent Psychiatry36: 701.
   PubMed Web of Science ®Google Scholar
• Kumra S, Robinson P, Tambyraja R, Jensen D, Schimunek C, Houri A, Reis T, Lim K. 2012. Parietal lobe volume deficits in adolescents with schizophrenia and adolescents with cannabis use disorders. Journal of American Academy of Child and Adolescent Psychiatry5: 171–180.
   Web of Science ®Google Scholar
• Kumra S, Schulz SC. 2008. Research progress in early onset schizophrenia. Editorial. Schizophrenia Bulletin34: 15–17.
   PubMed Web of Science ®Google Scholar
• Kunugi H, Nanko S, Murray RM. 2001. Obstetric complications and schizophrenia: prenatal underdevelopment and subsequent neurodevelopmental impairment. British Journal of Psychiatry Supplement40: 25–29.
   Google Scholar
• Lehman AF, Steinwachs DM. 1998. Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophrenia Bulletin24: 1–10.
   PubMed Web of Science ®Google Scholar
• Lieberman JA. 1993. Prediction of outcome in first episode schizophrenia. Journal of Clinical Psychiatry54: 13–17.
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Perkins D, Belger A, Chakos M, Jarskog F, Boteva K, Gilmore J. 2001. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biological Psychiatry1: 884–897.
   Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK. 2005. Clinical antipsychotic trials of intervention effectiveness [CATIE] effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine353: 1209–1223.
   PubMed Web of Science ®Google Scholar
• Marshall M, Lewis S, Lockwood A, Drake R, Jones P, Croudace T. 2005. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: A systematic review. Archives of General Psychiatry. 62: 975–983.
   PubMed Web of Science ®Google Scholar
• Masi G, Cosenza A, Brovedani P. 2003. A three-year naturalistic study of 53 preschool children with pervasive developmental disorder treated with risperidone. Journal of Clinical Psychiatry64: 1039–1047.
   PubMed Web of Science ®Google Scholar
• Masi G, Liboni F. 2011. Management of schizophrenia in children and adolescents: Focus on pharmacotherapy. Drugs72: 179–208.
   Web of Science ®Google Scholar
• McClellan, Stock S. 2013. Practice parameter for the assessment and treatment of children with schizophrenia. Journal of the American Academy of Child and Adolescent Psychiatry52: 976–990.
   PubMed Web of Science ®Google Scholar
• McGlashan TH. 1996. Early detection and intervention in schizophrenia research. Schizophenia Bulletin22: 327–345.
   PubMed Web of Science ®Google Scholar
• McGorry PD, Chanen A, McCarthy E. 1991. Posttraumatic stress disorder following recent-onset psychosis. Journal of Nervous and Mental Disease197: 253–258.
   Web of Science ®Google Scholar
• McGorry PD, Killackey E, Yung A. 2008. Early intervention in psychosis: concepts, evidence and future directions. World Psychiatry7: 148–156.
   PubMed Web of Science ®Google Scholar
• McGorry PD, Singh BS. 1995. Schizophrenia: Risk and possibility. In: Raphael B, Burrows GD (eds), Handbook of preventive psychiatry. New York: Elsevier. pp 492–514.
   Google Scholar
• McIntyre RS, Jerrell JM. 2008. Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents. Archives of Pediatrics & Adolescent Medicine162: 929–935.
   PubMed Web of Science ®Google Scholar
• Mueser K, McGurk SR. 2004. Schizophrenia. Lancet363: 2063–2072.
   PubMed Web of Science ®Google Scholar
• Ordonez AE, Bobb A, Greenstein D, Baker N, Sporn A, Lenane M, Malaspina D, Rapaport J, Gogtay N. 2005. Lack of evidence for elevated obstetric complications in childhood onset schizophrenia. Biological psychiatry58: 10–15.
   PubMed Web of Science ®Google Scholar
• Perkins DO. 2002. Predictors of noncompliance in patients with schizophrenia. Journal of Clinical Psychiatry63: 1121–1128.
   PubMed Web of Science ®Google Scholar
• Perkins DO, Gu H, Boteva K. 2005. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. American Journal of Psychiatry162: 1785–1804.
   PubMed Web of Science ®Google Scholar
• Petersen L, Jeppesen P, Thorup A. 2005. A randomised multicentre trial of integrated versus standard treatment for patients with a first episode of psychotic illness. British Medical Journal17: 602–605.
   Web of Science ®Google Scholar
• Rani FA, Byrne PJ, Murray ML. 2009. Paediatric atypical antipsychotic monitoring safety (PAMS) study: pilot study in children and adolescents in secondary and tertiary care settings. Drug Safety32: 325–333.
   PubMedGoogle Scholar
• Rapoport JL, Addington AM, Frangou S. 2005. The neuro-developmental model of Schizophrenia Update. Molecular Psychiatry10: 434–449.
   PubMed Web of Science ®Google Scholar
• Remschmidt H. 2002. Early-onset schizophrenia as a progressive-deteriorating developmental disorder: evidence from child psychiatry. Journal Neural Transmission109: 101–117.
   PubMed Web of Science ®Google Scholar
• Robinson DG, Woerner MG, Delman HM, Kane JM. 2005. Pharmacological treatments for first-episode schizophrenia. Schizophrenia Bulletin31: 705–722.
   PubMed Web of Science ®Google Scholar
• Rubino T, Parolaro D. 2014. Cannabis abuse in adolescence and the risk of psychosis: A brief review of the pre-clinical evidence. Progress in Neuro-Psychopharmacology and Biological Psychiatry52: 41–44.
   PubMed Web of Science ®Google Scholar
• Ruhrmann S, Schultze-Lutter F, Klosterkotter J. 2010. Sub-threshold states of psychosis—A challenge to diagnosis and treatment. Clinical Neuropsychiatry7: 72–87.
   Google Scholar
• Scott J, Chant D, Andrews G .2006. Psychotic-like experiences in the general community: the correlates of CIDI psychosis screen items in an Australian sample. Psychological Medicine36: 231–238.
   PubMed Web of Science ®Google Scholar
• Sikich L, Frazier JA, McClellan J. 2008. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizoaffective disorder: findings from the treatment of early-onset schizophrenia spectrum disorder (TEOSS) study. American Journal of Psychiatry165: 1420–1431.
   PubMed Web of Science ®Google Scholar
• Sikich L, Hamer R, Bashford R, Sheitman B, Lieberman JA. 2004. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacology29:133–145.
   PubMed Web of Science ®Google Scholar
• Spencer E, Birchwood M, McGovern D. 2001. Management of first episode psychosis. Advances in Psychiatric Treatment7: 133–142.
   Google Scholar
• Spencer EK, Kafantaris V, Padron-Gayol MV.1992. Haloperidol in schizophrenic children: early findings from a study in progress. Psychopharmacology Bulletin46: 969–978.
   Google Scholar
• Steen RG, Mull C, McClure R, Hamer RM, Lieberman JA. 2006. Brain volume in first-episode schizophrenia: Systematic review and meta-analysis of magnetic resonance imaging studies. British Journal of Psychiatry188: 510–518.
   PubMed Web of Science ®Google Scholar
• Susce MT, Villanueva N, Diaz FJ, DeLeon J. 2005.Obesity and associated complications in patients with severe mental illnesses: a cross-sectional survey. Journal of Clinical Psychiatry66: 167–173.
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Wahlbeck K, Lönnqvist J. 2006. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. British Medical Journal333: 224–227.
   PubMed Web of Science ®Google Scholar
• Woods SW, Martin A, Spector SG, McGlashan TH. 2002. Effects of development on olanzapine-associated adverse events. Journal of the American Academy of Child and Adolescent Psychiatry41: 1439–1446.
   PubMed Web of Science ®Google Scholar
• Yung AR, Nelson B, Stanford C 2008. Validation of “prodromal” criteria to detect individuals at ultra high risk of psychosis: 2 year follow-up. Schizophrenia Research105: 10–17.
   PubMed Web of Science ®Google Scholar
• Yung AR, Phillips LJ, Yuen HP. 2004. Risk factors for psychosis in an ultra high risk group: Psychopathology and clinical features. Schizophrenia Research67: 131–142.
   PubMed Web of Science ®Google Scholar
• Zhornitsky S, Stip E. 2012. Oral versus long-acting injectable antipsychotics in the treatment of schizophrenia and special populations at risk for treatment nonadherence: A systematic review. Schizophrenia Research and Treatment, 2012: 407171.
   Google Scholar